Canada Fragment-Based Drug Discovery Market Size & Outlook, 2025-2033
Canada Fragment-Based Drug Discovery Market Insights
- Based on Reed Intelligence findings, the Canada Fragment-Based Drug Discovery Market reached USD 53.41 Million in 2024 and is estimated to attain USD 145.69 Million by 2033.
- From 2025 to 2033, the Canada market is expected to grow at a steady CAGR of 11.82%.
- Within the By Service Components category, Fragment Screening dominated in 2024 in terms of market size contribution.
- Over the forecast period, Fragment Optimization is forecasted to deliver the fastest growth, positioning it as the most lucrative By Service Components segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, Canada represented 6.14% of the overall global Fragment-Based Drug Discovery Market size.
- United States is projected to lead the global Fragment-Based Drug Discovery Market size by 2033.
- Across North America, United States is anticipated to hold the dominant position in market size by 2033.
- Canada is forecasted to expand at the fastest pace in North America, attaining USD 145.98 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 53.41 Million |
| Market Size In 2033 | USD 145.69 Million |
| Largest segment | Fragment Screening |
| Units | Revenue in USD Million |
| CAGR | 11.82% (2025-2033) |
| Segmnetation Covered | |
| By Service Components |
|
| By End-User |
|
| By Applications |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Canada Fragment-Based Drug Discovery Market By Service Components 2025-2033 (USD Million)
| By Service Components | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragment Screening | XX.x | XX.x | XX.x | 30.26 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Fragment Optimization | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Canada Fragment-Based Drug Discovery Market By End-User 2025-2033 (USD Million)
| By End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceutical Companies | XX.x | XX.x | XX.x | 24.27 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| CROs | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Academic and Research Institutions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Canada Fragment-Based Drug Discovery Market By Applications 2025-2033 (USD Million)
| By Applications | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | XX.x | XX.x | XX.x | 20.48 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Central Nervous System (CNS) Disorders | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Infectious Diseases | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cardiovascular Diseases | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Metabolic Disorders | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Inflammation and Autoimmune Diseases | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
